Medicenna Therapeutics (TSE:MDNA) has released an update.
Medicenna Therapeutics has announced that ASCO retracted the company’s abstract for an oral presentation due to an alleged policy violation, a decision Medicenna disputes. The issue involves distinctions between interim results presented at AACR and the complete data from a Phase 1 study intended for ASCO. Despite this setback, Medicenna plans to reveal the full data set from its ABILITY-1 trial of MDNA11, a promising cancer immunotherapy candidate, in a special virtual event within the next month.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
